Blepharitis is a chronic disorder that leads to inflammation of the eyelids. The disorder impacts the part of eyelid where eyelashes grow. The disease progresses when tiny oil glands near this area are clogged as the clogging leads to irritation and redness of the eyes. Blepharitis is evident with following symptoms: high sensitivity to light, loss of eyelashes, watery eyes, burning sensation in the eyes, greasy eyelids, itchy eyes, red and swollen eyes, flaking of skin around the eyes, crusted eyelashes after waking up, more frequent blinking, abnormal growth of eyelashes, and stinging sensation in the eyes. Blepharitis is also a cause of seborrheic dermatitis, a dandruff of the eyebrows and scalp. The condition can also lead to bacterial infection, clogged oil glands, malfunctioning of oil glands, and rosacea. Other effects include allergic reactions to eye medications, contact lens solutions or eye make-up and eyelash lice or mites.
𝐁𝐥𝐞𝐩𝐡𝐚𝐫𝐢𝐭𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐃𝐫𝐢𝐯𝐞𝐫𝐬
Increasing prevalence of ophthalmic disorders among the geriatric population is expected to boost growth of the blepharitis treatment market. For instance, according to a survey conducted by American Academy of Ophthalmology in 2014, blepharitis usually affects people above the age of 50 years. According to the same source, blepharitis is observed in 37% male ophthalmic patients and 47% in female ophthalmic patients.
𝐓𝐨 Get 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/1761
Moreover, increasing number of drugs in the pipeline is also expected to contribute to the market growth. For instance, ISV-305 sponsored by InSite Vision is in phase 3 clinical trials, ISV-305 treats patients with early symptoms of blepharitis. Key players in the market are focused on product development and launch in order to expand their product portfolio, thereby propelling the market growth. For instance, in 2015, BlephEx, a Franklin-based company launched Rysurg. It is used to clean eyelids and also maintains hygiene. According to a study conducted by American Academy of Ophthalmology in 2015, around 50% of ophthalmic patients suffer from symptoms of blepharitis and dry eyes. Constant use of this device helps prevent recurrence of blephairis and the treatment is pain-free. Key players in the market are also focused on adopting merger and acquisition strategies. For instance, in 2013, Shire Plc. acquired California-based ophthalmic company, SARcode Bioscience. The acquisition helped Shire Plc. to add new drug – Lifitegrast— to its specialist drug portfolio. In 2016, the U.S. Food and Drug Administration (FDA) approved Lifitegrast for the treatment of signs and symptoms of dry eye and blepharitis.
However, lack of awareness regarding the treatment of blepharitis and high cost of therapies used in the treatment of the condition is expected to hinder the market growth.
𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 – https://www.coherentmarketinsights.com/insight/request-sample/1761
Blepharitis Treatment Market Regional Analysis:-
North America Blepharitis treatment market is expected to hold dominant position due to increasing geriatric population, launch of new products, and increasing number of ophthalmic patients in the region. According to a survey conducted in the U.S., by Population Reference Bureau in 2016, states that the aging population increased by 24% as compared to 15% in 2014. Europe is expected to witness rapid growth due to new product launches of blepharitis drugs in the region. For instance, in 2017, Scope Ophthalmic launched Moist Heat Mask, a device that helps in the treatment of blepharitis by loosening the oil present in Meibomian glands and allowing it to flow more freely. It helps to soften eye lash debris, prevent the evaporation of natural tear film, restores moisture to the eye and also the surrounding area, as well as improves tear film lipid quality. In 2015, MiBo Medical Group, a U.S.-based company, launched MibO Thermoflo. This device helps in the treatment of blepharitis and dry eyes and is required to be gently massaged on the margins of the eyelids for a minimum of 12 minutes. In 2015, MiBo Medical Group launched Lid Pro, a device that is used to treat anterior Blepharitis. The region of Asia Pacific is expected to witness significant growth due to increasing prevalence of blepharitis. According to a study conducted by Journal of Clinical and Experimental Ophthalmology in 2016, signs and symptoms of blepharitis increased by 32% among the geriatric population as compared to 2014.
𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐫 𝐐𝐮𝐞𝐫𝐲 𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐛𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠, 𝐕𝐢𝐬𝐢𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/talk-to-analyst/1761
Blepharitis Treatment Market Key Players:-
Key players operating in the Blepharitis treatment market include Scope Ophthalmic Ltd, NovaBay Pharmaceuticals Inc, Thea Pharmaceuticals Ltd, Perrigo Laboratories, InSite Vision Incorporated, Merck & Co, and Novartis AG
𝐁𝐥𝐞𝐩𝐡𝐚𝐫𝐢𝐭𝐢𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐚𝐱𝐨𝐧𝐨𝐦𝐲:-
The global Blepharitis treatment market is segmented based on disease type, treatment type, distribution channel, and region.
By Disease Type:-
• Posterior Blepharitis
• Anterior Blepharitis
• Mixed Blepharitis
By Treatment Type:-
• Antibiotic Therapy
• Topical Corticosteroids
• Topical Antibodies
• Oral Antibodies
• Ointments
• Eye Cleansers
• Others
By Distribution Channel:-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region:-
• North America
• Europe
• Latin America
• Asia-Pacific
• Middle East
• Africa
𝐓𝐨 𝐃𝐢𝐫𝐞𝐜𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 – https://www.coherentmarketinsights.com/insight/buy-now/1761
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
